Iterion Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Iterion Therapeutics's estimated annual revenue is currently $1M per year.
- Iterion Therapeutics's estimated revenue per employee is $77,500
- Iterion Therapeutics's total funding is $21.4M.
Employee Data
- Iterion Therapeutics has 13 Employees.
- Iterion Therapeutics grew their employee count by 8% last year.
Iterion Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Director Clinical Operations | Reveal Email/Phone |
3 | President & CEO | Reveal Email/Phone |
Iterion Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is Iterion Therapeutics?
Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/ -catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and multiple solid tumor types. The Company is enrolling a Phase I clinical study to evaluate safety and efficacy of Tegavivint in patients with desmoid tumors.
keywords:N/A
$21.4M
Total Funding
13
Number of Employees
$1M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Iterion Therapeutics News
HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel...
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.9M | 13 | 0% | N/A |
#2 | $1.9M | 13 | N/A | N/A |
#3 | $1.1M | 13 | N/A | N/A |
#4 | $1.7M | 13 | N/A | N/A |
#5 | $3.1M | 13 | -35% | N/A |